path(HP:"Hemolytic anemia") association path(HP:"Paroxysmal nocturnal hemoglobinuria")

View Subject View Object

PubMed:29956069

Inhibition of the terminal complement cascade by eculizumab (inhibits the cleavage of C5 into C5a und C5b and thus the formation of the membrane attack complex 8, MAC C5b-C9) for the treatment of hemolytic paroxymal nocturnal hemoglobinuria (PNH) significantly prevented PNH-related symptoms in patients including abnormal thrombophilia, red blood cell destruction, and the extent of hemolysis [76].

Related Edges 6

• a(MESH:eculizumab) decreases path(HP:"Paroxysmal nocturnal hemoglobinuria")
• path(HP:"Paroxysmal nocturnal hemoglobinuria") association path(MESH:Hemolysis)
• path(HP:"Paroxysmal nocturnal hemoglobinuria") association path(MESH:Thrombophilia)
• path(HP:"Paroxysmal nocturnal hemoglobinuria") association path(HP:"Hemolytic anemia")
• path(MESH:Hemolysis) association path(HP:"Paroxysmal nocturnal hemoglobinuria")
• path(MESH:Thrombophilia) association path(HP:"Paroxysmal nocturnal hemoglobinuria")

Cell Ontology (CL)

erythrocyte

MeSH

Liver

MeSH

Sepsis

Text Location

Review

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.

---